Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19677984 | 0.93 | CA2 (0.79) | CA2MAPTKMT2AMEN1THRB | |
| SCHEMBL3870706 | 0.90 | CA2 (0.58) | CA2MAPTKMT2AMEN1THRB | |
| SCHEMBL19272462 | 0.89 | CA2 (0.56) | CA2MAPTKMT2AMEN1THRB | |
| SCHEMBL16393362 | 0.89 | CA2 (0.86) | CA2MAPTKMT2AMEN1STS | |
| SCHEMBL19272473 | 0.89 | CA2 (0.86) | CA2MAPTKMT2AMEN1STS | |
| SCHEMBL19286028 | 0.88 | CA2 (0.75) | CA2MAPTKMT2AMEN1THRB | |
| SCHEMBL3865655 | 0.84 | CA2 (0.64) | CA2MAPTKMT2AMEN1THRB | |
| SCHEMBL19677983 | 0.84 | MAPT (0.59) | CA2MAPTKMT2AMEN1THRB | |
| SCHEMBL19272464 | 0.84 | CA2 (0.62) | CA2MAPTKMT2AMEN1THRB | |
| SCHEMBL19677972 | 0.83 | MAPT (0.65) | CA2MAPTKMT2AMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273263-B2 | Pro-drug forming compounds | EVESTRA, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170349624-A1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA, INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349624-A1 | PRO-DRUG FORMING COMPOUNDS | SUCNR1, FURIN, PROKR2 | CA2 941/4885MAPT 3071/4885KMT2A 2831/4885 |
| US-10273263-B2 | Pro-drug forming compounds | SUCNR1, FURIN, OGFR | CA2 1019/4885MAPT 3110/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.